The broader health-care sector faced downward pressure during the session, reflecting a wider market rotation. As traders reassessed their portfolios, the retreat from defensive holdings underscored a renewed appetite for tech-focused assets. For AstraZeneca and Ionis, the failure of Wainua in pivotal testing marks a significant hurdle for the drug's development timeline, drawing immediate negative reactions from shareholders tracking the company's experimental pipeline.